{ "market" : {"NAME" : "U.S.", "ID" : "us_market", "TZ" : "ET", "TZOFFSET" : "-18000", "open" : "1259159414", "close" : "1259182814", "flags" : {}} , "STREAMER_SERVER" : "http://streamerapi.finance.yahoo.com","arrowAsChangeSign" : false,"throttleInterval": "1000"}
globenewswire

Achillion to Present At Upcoming Conferences

  • Press Release
  • Source: Achillion Pharmaceuticals, Inc
  • On 7:00 am EDT, Tuesday June 2, 2009

NEW HAVEN, Conn., June 2, 2009 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN - News), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will give a corporate overview and update on the Company's HCV programs at the following upcoming investment conferences:

Related Quotes

SymbolPriceChange
ACHN1.880.00
Chart for Achillion Pharmaceuticals, Inc.
{"s" : "achn","k" : "c10,l10,p20,t10","o" : "","j" : ""}



 * Noble Financial Capital Markets 5th Annual Emerging Growth Equity
   Conference -- June 9, 2009 at 1:20 p.m. at the Hard Rock Hotel in
   Hollywood, Florida
 * Needham and Company 8th Annual Life Sciences Conference -- June 10,
   2009 at 3:00 p.m. at the New York Palace Hotel in New York City

The live audio broadcasts and the subsequent archived webcasts of the Company presentation will be available on the Company's website, http://www.achillion.com, under the "News Center" section. The audio recording will be archived there for 30 days following the live presentation. Please connect to Achillion's website several minutes prior to the start of the presentation to ensure adequate time for any software downloads that may be necessary.

About Achillion

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The company's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease -- hepatitis, resistant bacterial infections and HIV. For more information on Achillion Pharmaceuticals, please visit the company's web site at www.achillion.com. ACHN-G

Contact:

Achillion Pharmaceuticals, Inc.
Mary Kay Fenton
(310) 691-7100
mfenton@achillion.com

Lippert/Heilshorn & Associates, Inc.
Investors:
Anne Marie Fields
(212) 838-3777
afields@lhai.com
Bruce Voss
(310) 691-7100
bvoss@lhai.com

Sponsored Links

Copyright © 2009 GlobeNewswire. All rights reserved. Redistribution of this content is expressly prohibited without prior written consent. GlobeNewswire makes no claims concerning the accuracy or validity of the information, and shall not be held liable for any errors, delays, omissions or use thereof.